Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has at present seven research departments and more than 230 employees. More than half of the staff are externally funded. Many of the researchers have national and international commissions and ongoing collaborations.
The research at the Institute was collectively described as "very good, on the border of outstanding" by an international panel evaluating Norwegian biomedical research on behalf of The Norwegian Research Council.
Scientific director
Scientific production - Institute for Cancer Research
| PubMed articles | Doctoral theses | |
| 2010 | so far | |
| 2009 | 191 | 22 |
| 2008 | 184 | 11 |
| 2007 | 161 | 16 |
| 2006 | 176 | 12 |
| 2005 | 154 | 12 |
Print this page [48378 visits]Latest news
Institute seminar March 10th 10.30
Gustav Gaudernack
The institute seminar on Wednesday March 10th is given by Gustav Gaudernack from the Department of Immunology. Title of his talk:
Cancer immunotherapy: From bench to bedside and from mutant ras to cancer stem cells
The seminar takes place in the Auditorium (New Research Building Montebello) and starts at 10:30.
Group at Institute for Cancer Research identifies new functional mechanism for a tumour suppressor
PhD student Antonia Sagona and her co-workers in Harald Stenmark´s group at the Centre for Cancer Biomedicine, Institute for Cancer Research, have uncovered a new functional mechanism for a known tumour suppressor, the class III phosphatidylinositol 3-kinase (PI3K-III), a protein complex that mediates formation of the membrane lipid, phosphatidylinositol 3-phosphate (PtdIns3P). The findings are published as a main article in the April 2010 issue (advance online publication 7 March 2010) of Nature Cell Biology (impact factor 17.774) .
Molecular Genetics group publish in Journal of Clinical Oncology
The "Molecular Genetics group" at the Department of Cancer Prevention, headed by Ragnhild A. Lothe, has recently published a translational research paper in the highly rated "Journal of Clinical Oncology" (journal impact factor 17.2). The article - entitled "Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group" is published in the "Translational oncology" section.
The first three authors are PhD candidate Helge R. Brekke (1st author), dr. Franclim Ribeiro and dr. Matthias Kolberg.
Mar 8, 2010
21st Meeting of the European Association for Cancer Research, 26 - 29 June 2010
Feb 25, 2010
Latest publications
Inst. for Cancer Research
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells
Cell Oncol, 32 (1), 11-27
PubMed 20203370
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase
J Cell Biol (in press)
PubMed 20194642
Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
Amino Acids (in press)
PubMed 20191297
Selected publications
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
p62, an autophagy hero or culprit?
Nat Cell Biol, 12 (3), 207-9
PubMed 20190829
(Impact 17.8)
Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group
J Clin Oncol (in press)
PubMed 20159821
(Impact 17.2)
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance
Pharmacogenomics J (in press)
PubMed 20157331
(Impact 5.4)
